



FY2023 H1 Financial Results



Revenue

¥2,101.7_B

+1.4% growth at CER



Core Operating
Profit

¥588.8B

-5.8% at Actual Exchange Rate,
-9.5% change at Constant
Exchange Rate (CER) reflects
generic impact, lower demand
for coronavirus vaccines and
increased investment in R&D
and data & technology

Core Operating
Profit Margin

28.0%

Reported
Operating Profit

¥119.2B

-53.2% change at Actual
Exchange Rate impacted
by large non-cash
impairments of intangible
assets



Our extensive portfolio of
Growth & Launch Products
continued to drive revenue
growth.

42%

Share of Total Revenue

+13%

Growth at CER



Core Revenue

¥3,980.0B

Core Operating Profit

¥1,015.0B

Core EPS

¥447

Raising full-year Core Revenue and Core EPS forecasts
to reflect updated foreign exchange and tax rate assumptions

No change to Management Guidance at CER

Core Revenue

Low-single-digit
% decline

Core Operating Profit

Low-10s
% decline

Core EPS

Low-20s
% decline





This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2023 Q2 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Core Revenue, Core Operating Profit, Core Operating Profit Margin, Core EPS, CER % Change, Net Debt, Adjusted EBITDA, and Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2023 Q2 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.